Determinants of long-term outcome in severe alcoholic hepatitis

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 6, 2013, Pages 584-595

  Potts, J R ^a,b   Goubet, S ^b   Heneghan, M A ^c   Verma, S ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b UK   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PENTOXIFYLLINE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL LIVER DISEASE; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATORENAL SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RECIDIVISM; SEVERE ALCOHOLIC HEPATITIS; SURVIVAL RATE; SURVIVAL TIME;

EID: 84883053432     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12427     Document Type: Article

References (39)

1. Sheron N, Gilmore I, Parsons C, Hawkey C, Rhodes J,. Projections of alcohol-related deaths in England and Wales-tragic toll or potential prize? Lancet 2012; 379: 687-8.
2. Carithers RL Jr, Herlong HF, Diehl AM, et al,. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110: 685-90.
3. Mathurin P, Lucey MR,. Management of alcoholic hepatitis. J Hepatol 2012; 56 (Suppl.): S39-45.
4. Mathurin P, O'Grady J, Carithers RL, et al,. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-60.
5. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C,. Systematic review: glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 1167-78.
6. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD,. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 37: 845-54.
7. Mathurin P, Duchatelle V, Ramond MJ, et al,. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110: 1847-53.
8. Alexander JF, Lischner MW, Galambos JT,. Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971; 56: 515-25.
9. O'Shea RS, Dasarathy S, McCullough AJ,. Alcoholic liver disease. Hepatology 2010; 51: 307-28.
10. European Association For The Study Of The Liver. EASL Clinical Practical Guidelines: management of Alcoholic Liver Disease. J Hepatol 2012; 57: 399-420.
11. Mathurin P, Abdelnour M, Ramond M-J, et al,. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003; 38: 1363-9.
12. Dominguez M, Rincõn D, Abraldes JG, et al,. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008; 103: 2747-56.
13. Local alcohol profile for England. Primary care trust profile-south east coast. Available at: http://www.lape.org.uk/. Accessed May 16, 2013.
14. Mookerjee RP, Lackner C, Stauber R, et al,. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol 2011; 55: 1103-11.
15. Forrest EH, Gleeson D,. Is a liver biopsy necessary in alcoholic hepatitis? J Hepatol 2012; 56: 1427-8.
16. Katoonizadeh A, Laleman W, Verslype C, et al,. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010; 59: 1561-9.
17. Forrest EH, Evans CDJ, Stewart S, et al,. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54: 1174-9.
18. Kamath PS, Wiesner RH, Malinchoc M, et al,. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
19. Biggins SW, Kim WR, Terrault NA, et al,. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-60.
20. Runyon BA,. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-107.
21. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V,. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-8.
22. Schemper M, Smith TL,. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-6.
23. Forrest EH, Morris AJ, Stewart S, et al,. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56: 1743-6.
24. Dunn W, Jamil LH, Brown LS, et al,. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353-8.
25. Vaa BE, Asrani SK, Dunn W, Kamath PS, Shah VH,. Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin Proc 2011; 86: 37-42.
26. Potts JR, Howard MR, Verma S,. Recurrent severe alcoholic hepatitis: clinical characteristics and outcomes. Eur J Gastroenterol Hepatol 2013; 25: 659-64.
27. Louvet A, Artru F, Colin M, et al,. Patients with severe alcoholic hepatitis and hepatorenal syndrome require a new therapeutic strategy. Hepatology 2012; 56 (S1): 986A-7A.
28. Veldt BJ, Lainé F, Guillygomarc'h A, et al,. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36: 93-8.
29. Pessione F, Ramond M, Peters L, et al,. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23: 45-53.
30. Alcohol consumption and harm in the UK and EU. Institute of Alcohol Studies Factsheet. Available at: http://www.ias.org.uk/resources/factsheets/ harm-ukeu.pdf. Accessed September 10, 2012.
31. Verrill C, Markham H, Templeton A, Carr NJ, Sheron N,. Alcohol-related cirrhosis-early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 2009; 104: 768-74.
32. Naveau S, Chollet-Martin S, Dharancy S, et al,. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-7.
33. Mathurin P, Moreno C, Samuel D, et al,. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365: 1790-800.
34. Addolorato G, Leggio L, Ferrulli A, et al,. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915-22.
35. Shawcross DL, O'Grady JG,. The 6-month abstinence rule in liver transplantation. Lancet 2010; 376: 216-7.
36. Zimmerman HJ, Maddrey WC,. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22: 767-73.
37. Myers RP, Shaheen AAM, Li B, Dean S, Quan H,. Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin Gastroenterol Hepatol 2008; 6: 918-25.
38. Dart RC, Green JL, Kuffner EK, Heard K, Sproule B, Brands B,. The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol-a randomized study. Aliment Pharmacol Ther 2010; 32: 478-86.
39. Sohrabpour AA, Mohamadnejad M, Malekzadeh R,. Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 2012; 36: 824-32.